These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31868556)

  • 1. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1122-1127. PubMed ID: 31868556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
    J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
    J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
    J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
    Newcomb LF; Schenk JM; Zheng Y; Liu M; Zhu K; Brooks JD; Carroll PR; Dash A; de la Calle CM; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; McKenney JK; Morgan TM; Tretiakova MS; Wagner AA; Nelson PS; Lin DW
    JAMA; 2024 Jun; 331(24):2084-2093. PubMed ID: 38814624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
    BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
    Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
    Thomsen FB
    Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
    Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
    J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Chesnut GT; Vertosick EA; Benfante N; Sjoberg DD; Fainberg J; Lee T; Eastham J; Laudone V; Scardino P; Touijer K; Vickers A; Ehdaie B
    Eur Urol; 2020 Apr; 77(4):501-507. PubMed ID: 31874726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.